38 results about "Mini tablets" patented technology

The present invention relates to an extended release once daily pharmaceutical formulation comprising venlafaxine hydrochloride and pharmaceutically acceptable excipients. More particularly, the present invention relates to an extended release composition in the form of mini-tablets which are incorporated in hard gelatin capsules.

The present invention relates to microspheres and compositions comprising a plurality of microspheres, wherein the microspheres are perfectly spherical and have a moisture content less than 1%, and the method of manufacturing the same. The present invention is useful in the manufacture of sustained and modified release active pharmaceutical ingredient (API) microspheres, as a free flowing excipient for mini-tablets and in the manufacture of API dispersions.

Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.

The invention discloses a memantine hydrochloride sustained release preparation. The memantine hydrochloride sustained release preparation comprises a memantine hydrochloride sustained release mini-tablet formed by a tablet core and a coating film. The weight of the coating film is 0-30% of the weight of the tablet core. Equipment for producing the sustained release mini-tablet is simple and is similar to equipment for producing common tablets, besides changes of the diameter size of a punch, and therefore industrial production of the sustained release mini-tablet can be easily achieved. After process parameters of the mini-tablet are determined, the sizes of obtained tablets are largely the same, in-batch differences or differences among batches are almost nonexistent, and the quality is easy to control.

Innovative instrument holders used for minimally invasive surgical simulation and training are disclosed when used in conjunction with a smartphone, tablet or mini-tablet computer enabling visualization of the surgical field. The surgical field used with these instrument holders can include animal models, physical models, and both virtual and augmented reality models. Some embodiments can be used with applications that can be downloaded to the smartphone, tablet or mini-tablet computer in order to enhance specific hand-eye coordination tasks. Some embodiments can be used as an adjunct surgical trainer for endoscopy, colonoscopy, and other minimally invasive gastrointestinal and gynecological surgical procedures using surgical instruments that incorporate fiber optics.

Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry. The unexpected release kinetics of the 5 mg pellet provides an ideal implant for post surgical analgesia. These implants solve a significant problem facing scientists who use rodents in research and abide by international of animal welfare.

The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes.